Compare BioNTech SE - ADR (BNTX) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.95. The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | GSG | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $119.34 | $34.77 |
52-Week Low | $83.89 | $22.06 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
GSG trades at $30.52, up 3.6% with a bullish technical signal. Moving averages and oscillators support upward momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights institutional shifts toward commodities, aligning with GSG's focus. Key support lies near $30, with resistance at $31.
The outlook remains positive amid commodity-driven market themes, but overbought technicals and reliance on macroeconomic trends pose risks. Upside depends on sustained commodity demand and institutional inflows, while volatility may test near-term support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
